TMDX
What one share of TransMedics Group holds
Electromedical and Electrotherapeutic Apparatus
We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide.
TransMedics Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $17.40 |
|---|---|
| Profit | $4.02 |
| Capex (buildings and equipment) | $1.74 |
| Free cash flow | $2.06 |
| Cash and investments | $14.18 |
| Book value | $14.96 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $9.58 | −$17.48 | $0.31 | −$19.43 | — | −$137.56 |
| 2019 | $1.66 | −$2.36 | $0.01 | −$2.28 | $0.00 | $2.58 |
| 2020 | $1.04 | −$1.16 | $0.02 | −$1.24 | $0.00 | $3.82 |
| 2021 | $1.10 | −$1.60 | $0.13 | −$1.17 | $0.00 | $2.44 |
| 2022 | $3.16 | −$1.23 | $0.40 | −$1.95 | $0.00 | $5.83 |
| 2023 | $7.43 | −$0.77 | $4.67 | −$5.07 | $0.00 | $4.20 |
| 2024 | $12.54 | $1.01 | $3.68 | −$2.30 | $0.00 | $6.80 |
| 2025 | $14.94 | $4.87 | $1.46 | $3.30 | $0.00 | $13.81 |